Skip to main content
Premium Trial:

Request an Annual Quote

ABI's Burzik Steps Down; Roche's Dreismann Lands Another Board Appointmnt; Quantum Genomics and Biotrove Name New Directors

NEW YORK (GenomeWeb News) — Applied Biosystems President Cathy Burzik stepped down a little more than two years after being tapped to run the business after Mike Hunkapiller retired.
She left to take over as CEO of Kinetic, a San Antonio-based company specializing in advanced wound care and therapeutic surfaces.
Applera President and CEO Tony White has become interim president “partnering with the AB leadership team. ABI said the changes are effective immediately.
Burzik took over the helm of ABI after Michael Hunkapiller retired in August 2004. She joined ABI in September 2003 from Johnson & Johnson, where she was president of the company’s Ortho-Clinical Diagnostics business. Before being named president of ABI Burzik had been the company's executive vice president and COO.

Toxicogenomics company Iconix Biosciences, formerly Iconix Pharmaceuticals, has named Heiner Dreismann to its board of directors.
Dreismann previously was president and CEO of Roche Molecular Systems
The company also announced it has changed its name to reflect its emphasis on toxicogenomics products.
Last month ChondroGene named Dreismann to its board.

Quantum Genomics said it has named Jean-Pierre Riffaud to lead its preclinical development unit. The Jersey City, NJ-based company specializes in developing treatments for metabolic and cardiovascular pathologies.
Riffaud formerly served in preclinical development at Cellpep, Nicox and at several French pharmaceutical companies. 

Biotrove has appointed Edward Erickson to its board of directors. Erickson previously served as president, CEO, or director at eight biomedical companies, including Megabios and Depotech.

London-based DeltaDOT has named Dave Byatt, former engineer and designer at Aim Technology, as its new director of operations, the company said.
The company also has appointed Frank Smith, a product manager from Genomic Solutions, as its new chief commercial officer.
DeltaDOT, a spin-off from London’s Imperial College of Science, Technology and Medicine, focuses on biomolecular separation and DNA/RNA analysis.   

Brendan McKernan, co-founder and vice president of operations at Agencourt Biosciences, has been named the 2006 William F. Glaser Entrepreneur of the Year by the Rensselaer Polytechnic Institute.
The institute said McKerman is the youngest winner of the award and is the first graduate of Rensselaer’s Management and Technology MBA program to be so honored.

Protein Discovery has added John Yates III to its scientific advisory board, the company said today. Yates is a professor of cell biology at the proteomic mass spectrometry lab at the Scripps Research Institute.

Doris Tsao, a researcher at the University of Bremen, in Germany, was awarded the Eppendorf & Science Prize for Neurobiology.
Tsao won $25,000 for her work entitled “What’s in a face? Recognition at the cellular level.” 
The prize is awarded to young scientists who received a PhD or MD in the previous 10 years, and this year the committee was chaired by Science editor Donald Kennedy. 

The National Center for Genome Resources has named Scott Wolff as director of software engineering, the organization reported.
Wolff, senior engineer and manager at Sun Microsystems from 2001 to 2006, will lead NCGR’s software development teams, technical projects portfolio, Web-based information resources and applications for population genetics, molecular diagnostics research and semantic Web technology projects, NCGR said.

Bioconjugation company SoluLink announced this week that it has formed a scientific advisory board, including:
David Ward, deputy director of the Nevada Cancer Institute; Matt Francis, assistant professor at UC Berkeley; Bob Brown, vice president of research and technology at Genta; Martin Latterich, associate professor at McGill University; and C. Satishchandran, senior vice president of R&D, Nucleonics

The Ontario Institute for Cancer Research this summer named Thomas Hudson as its new president and scientific director.
An early member of the Human Genome Project, Hudson was a director at the Whitehead Institute for Biomedical Research at MIT, and at the MIT Centre for Genome Research. He later became the founder and director of the McGill University and Genome Quebec Innovation Centre, where he will remain until 2007.
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.